Trials / Completed
CompletedNCT06649006
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
A Phase 1b Open-label Study to Investigate Safety, Tolerability and Pharmacokinetics of Intravenous Blinatumomab in Japanese Adult Subjects With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of the study is to evaluate safety and tolerability of blinatumomab in adult Japanese participants with newly diagnosed B-ALL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Blinatumomab | IV infusion |
Timeline
- Start date
- 2025-01-08
- Primary completion
- 2025-07-30
- Completion
- 2025-12-04
- First posted
- 2024-10-18
- Last updated
- 2026-01-08
Locations
6 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06649006. Inclusion in this directory is not an endorsement.